Acute and persistent responses after H5N1 vaccination in humans

人类接种H5N1疫苗后的急性及持续性反应

阅读:1
作者:Richard Apps ,Angélique Biancotto ,Julián Candia ,Yuri Kotliarov ,Shira Perl ,Foo Cheung ,Rohit Farmer ,Matthew P Mulè ,Nicholas Rachmaninoff ,Jinguo Chen ,Andrew J Martins ,Rongye Shi ,Huizhi Zhou ,Neha Bansal ,Paula Schum ,Matthew J Olnes ,Pedro Milanez-Almeida ,Kyu Lee Han ,Brian Sellers ,Mario Cortese ,Thomas Hagan ,Nadine Rouphael ,Bali Pulendran ,Lisa King ,Jody Manischewitz ,Surender Khurana ,Hana Golding ,Robbert G van der Most ,Howard B Dickler ,Ronald N Germain ,Pamela L Schwartzberg ,John S Tsang

Abstract

To gain insight into how an adjuvant impacts vaccination responses, we use systems immunology to study human H5N1 influenza vaccination with or without the adjuvant AS03, longitudinally assessing 14 time points including multiple time points within the first day after prime and boost. We develop an unsupervised computational framework to discover high-dimensional response patterns, which uncover adjuvant- and immunogenicity-associated early response dynamics, including some that differ post prime versus boost. With or without adjuvant, some vaccine-induced transcriptional patterns persist to at least 100 days after initial vaccination. Single-cell profiling of surface proteins, transcriptomes, and chromatin accessibility implicates transcription factors in the erythroblast-transformation-specific (ETS) family as shaping these long-lasting signatures, primarily in classical monocytes but also in CD8+ naive-like T cells. These cell-type-specific signatures are elevated at baseline in high-antibody responders in an independent vaccination cohort, suggesting that antigen-agnostic baseline immune states can be modulated by vaccine antigens alone to enhance future responses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。